

## DAFTAR PUSTAKA

- Abi-Dargham, A. 2004. Do we still believe in the dopamine hypothesis? New data bring new evidence. *Int J Neuropsychopharmacol*, 7 Suppl 1, S1-5.
- Alit, M. D. 2016. *Keefektifan Pemberian Clozapin Dibandingkan Risperidon Terhadap PANSS dan Kadar Interleukin-2 Pada Pasien Skizofrenia Kronis Eksaserbasi Akut.*, Universitas Sebelas Maret Surakarta.
- American Psychiatric Association 2000a. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association.
- American Psychiatric Association 2000b. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. In: IKAWATI, Z. (ed.) 2018, *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat edisi 1*. Karangkajen, Yogyakarta: Bursa Ilmu.
- American Psychiatric Association 2013a. Diagnostic and Statistical Manual of Mental Disorder : DSM-V. In: IKAWATI, Z. (ed.) 2018, *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat edisi 1*. Karangkajen, Yogyakarta: Bursa Ilmu.
- American Psychiatric Association 2013b. Schizophrenia. In: MARIE A. CHISHOLM-BURNS., TERRY L. SCHWINGHAMMER., BARBARA G. WELLS., PATRICK M. MALONE., JILL M. KOLESAR. & JOSEPH T. DIPIRO. (eds.) 2016, *Pharmacotherapy Principles & Practice Fourth Edition*. New York: McGraw-Hill Education.
- Amir & Nurmiati. 2008. *RE: Pengenalan Instrument PANSS*.
- Anil, Y. A., Kivircik, A. B., Turgut, T. I., Tümüklü, M., Yazici, M. K., Alptekin, K., Ertuğrul, A., Jayathilake, K., Göğüş, A. & Tunca, Z. 2005. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. *The Journal of clinical psychiatry*, 66, 63.
- Arisyandi, R. R. 2015. *Pengaruh Kunjungan Keluarga Terhadap Skor Positive and Negative Symptom Scale (Panss) Pada Pasien Skizofrenia Yang Dirawat Inap Di Rumah Sakit Jiwa Daerah Sungai Bangkong*. Tanjungpura University.
- Baldessarini, R. J., and F. R. Frankenburg 1991. "A novel antipsychotic agent.". *N Engl J Med* 324.11, 746-754.

- Blessing, I. O., Iyalomhe, G. B. S., George, E. O., Okojie, F. O. & Solomon, A. O. 2013. Effect of chlorpromazine and haloperidol combination on lipid profile in Nigeria schizophrenic patients. *International Journal of Medical and Pharmaceutical Sciences*, 3(12), 11-20.
- Bruijnzeel, D., Suryadevara, U. & Tandon, R. 2014. Antipsychotic treatment of schizophrenia: an update. *Asian J Psychiatr*, 11, 3-7.
- Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R. & Keller, W. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull*, 36, 71-93.
- Buckley, P. F., Miller, B. J., Lehrer, D. S. & Castle, D. J. 2008. Psychiatric comorbidities and schizophrenia. *Schizophrenia bulletin*, 35, 383-402.
- Crilly, J. 2007. The history of clozapine and its emergence in the US market: a review and analysis. *Hist Psychiatry*, 18, 39-60.
- Crismon, M. L., Argo, T. R. & Buckley, P. F. 2008. Schizophrenia. In: DIPIRO, J. T., TALBERT, R. L., YEE, G. C., MATZKE, G. R., WELLS, B. G. & POSEY, L. M. (eds.) 2008, *Pharmacotherapy A Pathophysiologic Approach, 7th Edition, Edition*, 1099-1122. New York: McGraw Hill Companies.
- Dahlan, M. S. 2016a. *Analisis Multivariate Regresi Logistik, Edisi 4*, Jakarta, Epidemiologi Indonesia.
- Dahlan, M. S. 2016b. *Besar Sampel Dalam Penelitian Kedokteran Dan Kesehatan, Edisi 4*, Jakarta, Epidemiologi Indonesia.
- Damayantie, N., Rusmimpong, R. & Elly, A. 2019. Hubungan Pengetahuan Dan Dukungan Keluarga Dengan Kepatuhan Kontrol Berobat Pasien Skizofrenia Di Poli Jiwa Rsjd Provinsi Jambi Tahun 2018. *Jurnal Bahana Kesehatan Masyarakat (Bahana of Journal Public Health)*, 3, 1-5.
- Depkes 2004. Pedoman penggolongan dan diagnosis gangguan jiwa di Indonesia. Jakarta: Departemen Kesehatan.
- Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G. & Posey, L. M. 2008. *Pharmacotherapy A Pathophysiologic Approach, 7th Edition, Edition*,. McGraw Hill Companies: New York.
- Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G. & Posey, L. M. 2017. *Pharmacotherapy A Pathophysiologic Approach Tenth Edition*. New York: McGraw Hill Companies.

- Durand, V. M. & Barlow, D. H. 2006. Intisari psikologi abnormal. *Yogyakarta: Pustaka Pelajar*.
- Ezeme, M. S., Uwakwe, R., Ndukuba, A. C., Igwe, M. N., Odinka, P. C., Amadi, K. & Obayi, N. O. 2016. Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria. *Afr Health Sci*, 16, 1036-1044.
- Gibson., Aaron P., Nick C. Patel. & Lauriello, J. 2008. "Antipsychotic combinations blind step or logical? Though unsupported by evidence, using > 1 antipsychotic may make sense for some treatment-resistant patients.". *Current Psychiatry* 7, 40.
- Goff, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., Bierer, M., Duckworth, K. & Sacks, F. M. 2005. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. *The Journal of clinical psychiatry*.
- Goff, D. C., Henderson, D. C. & Amico, E. 1992. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. *Am J Psychiatry*.
- Gupta, S., Black, D. W. & Smith, D. A. 1994. Risperidone: review of its pharmacology and therapeutic use in schizophrenia. *Annals of Clinical Psychiatry*, 6, 173-180.
- Herz, M. I. & Marder, S. R. 2002. Schizophrenia: comprehensive treatment and management. Philadelphia: Lippincott Williams & Wilkins.
- Hukkanen, J., Jacob III, P., Peng, M., Dempsey, D. & Benowitz, N. L. 2011. Effect of nicotine on cytochrome P450 1A2 activity. *British journal of clinical pharmacology*, 72, 836.
- Ikawati, Z. 2018. *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat, Pertama*, Karangkajen, Yogyakarta, Bursa Ilmu.
- Irman, V., Patricia, H. & Srimayenti 2018. Faktor-faktor yang berhubungan dengan kepatuhan keluarga dalam mengontrol minum obat pada pasien Skizofrenia. *Jurnal Ilmu Kesehatan*, Volume 2 No.1.
- Isuru, A. & Rajasuriya, M. 2019. Tobacco smoking and schizophrenia: re-examining the evidence. *BJPsych Advances*, 25, 363-372.
- Jones, P. & Buckley 2006. *Schizophrenia*, London, Mosby.

- Kane, J. M., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Rosenheck, R. A., Addington, J., Brunette, M. F., Correll, C. U. & Estroff, S. E. 2015a. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. *American Journal of Psychiatry*, 173, 362-372.
- Kane, J. M., Schooler, N. R., Patricia Marcy, B., Correll, C. U., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Addington, J., Estroff, S. E. & Robinson, J. 2015b. Original research the RAISE early treatment program for first-episode psychosis: Background, rationale, and study design. *J Clin Psychiatry*, 76, 240-6.
- Kaplan, H. I., Sadock, B. J. & Grebb, J. A. 1997. Sinopsis Psikiatri Ilmu Pengetahuan Perilaku Psikiatri Klinis Jilid 2. *Edisi Ke-7. Alih Bahasa: Dr. Widjaja Kusuma. Jakarta: Binarupa Aksara.*
- Kaplan, H. I., Sadock, B. J. & Grebb, J. A. 2010. Sinopsis psikiatri jilid 1. *Terjemahan Widjaja Kusuma. Jakarta: Binarupa Aksara*, 704-43.
- Katona, Cornelius, Claudia Cooper & Robertson, M. 2012. *At a Glance Psikiatri edisi keempat*, Jakarta, Erlangga.
- Kementrian Kesehatan 2015. Keputusan Menteri Kesehatan Republik Indonesia : Nomor HK.02.02/MENKES/73/2015 Tentang Pedoman Nasional Pelayanan Kedokteran Jiwa. *In: KEMENTRIAN KESEHATAN RI (ed.)*. Jakarta: Menteri Kesehatan.
- Kementrian Kesehatan 2018. Hasil Utama Riskesdas. *In: RI., B. P. D. P. K. (ed.)*. Jakarta: Kementrian Kesehatan.
- Krystal, J. H. & Anticevic, A. 2015. Toward illness phase-specific pharmacotherapy for schizophrenia. *Biol Psychiatry*, 78, 738-40.
- Kurnia, F. Y. P., Tyaswati, J. E. & Abrori, C. 2015. Faktor-faktor yang Mempengaruhi Kekambuhan pada Pasien Skizofrenia di RSD dr. Soebandi Jember (Factors that Affect the Recurrence of Schizophrenia at dr. Soebandi Hospital, Jember). *Pustaka Kesehatan*, 3, 400-407.
- Lehman, A., Lieberman JA., Dixon LB., McGlashan TH., Miller AL., Perkins DO. & Kreyenbuhl J. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*, 161(2 Suppl), 1-56.
- Lv, Y., Wolf, A. & Wang, X. 2013. Experienced stigma and self-stigma in Chinese patients with schizophrenia. *General hospital psychiatry*, 35, 83-88.

- Maramis & Willy, F. 2005. *Catatan Ilmu Kedokteran Jiwa, Cetakan Kesembilan*, Surabaya, Airlangga University Press.
- Marangell, Lauren B. & Martinez., J. M. 2006. Concise guide to psychopharmacology. *American Psychiatric Pub.*
- Marie , A. C.-B., Terry L. Schwinghammer., Barbara G. Wells., Patrick M. Malone., Jill M. Kolesar. & Joseph T. DiPiro. 2016. *Pharmacotherapy Principles & Practice Fourth Edition*. New York: McGraw-Hill Education.
- McGorry, P. D. 2013. The next stage for diagnosis: validity through utility. *World Psychiatry*, 12, 213.
- McGrath, J., Saha, S., Chant, D. & Welham, J. 2008. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiologic reviews*, 30, 67-76.
- Miller, B. J., Culpepper, N., Rapaport, M. H. & Buckley, P. 2013. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. *Prog Neuropsychopharmacol Biol Psychiatry*, 42, 92-100.
- Montoya, A., Amparo Valladares., Luis Lizan., Luis San., Rodrigo Escobar. & Silvia Paz. 2011. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. *Health and Quality of Life Outcomes*, 9:18, 1-11.
- Nucifora, F. C., Jr., Mihaljevic, M., Lee, B. J. & Sawa, A. 2017. Clozapine as a Model for Antipsychotic Development. *Neurotherapeutics*, 14, 750-761.
- Nuryati 2017. Bahan Ajar Rekam Medis dan Informasi Kesehatan Farmakologi. *In: KESEHATAN*, B. P. D. P. S. D. (ed.). Jakarta: Kementerian Kesehatan Republik Indonesia.
- Nyer, M., Kasckow, J., Fellows, I., Lawrence, E. C., Golshan, S., Solorzano, E. & Zisook, S. 2010. The relationship of marital status and clinical characteristics in middle-aged and older patients with schizophrenia and depressive symptoms. *Ann Clin Psychiatry*, 22, 172-179.
- Obermeier, M., Schennach-Wolff, R., Meyer, S., Möller, H.-J., Riedel, M., Krause, D. & Seemüller, F. 2011. Is the PANSS used correctly? a systematic review. *BMC psychiatry*, 11, 113.
- Oktovina, M. N. 2009. *Evaluasi Rejimen Obat Pasien Schizophrenia Pada Unit Rawat Jalan dan Rawat Inap Setelah Uji Coba Kebijakan INA-DRG di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Jakarta*. Universitas Indonesia.

- Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N. & Adams, C. E. 2017. Antipsychotic combinations for schizophrenia. *Cochrane Database Syst Rev*, 6, CD009005.
- Osser, D. N., Roudsari, M. J. & Manschreck, T. 2013. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. *Harv Rev Psychiatry*, 21, 18-40.
- Park, S. G., Bennett, M. E., Couture, S. M. & Blanchard, J. J. 2013. Internalized stigma in schizophrenia: relations with dysfunctional attitudes, symptoms, and quality of life. *Psychiatry research*, 205, 43-47.
- Patel, M. 2010. Tobacco dependence and schizophrenia. A Complex Correlation. *Journal of Young Investigators*, 19, 1-7.
- PDSKJI 2011. Konsensus penatalaksanaan gangguan skizofrenia. *Astra Zeneca Indonesia, Jakarta*.
- Peng, H., Kuang, Y. & Huang, X. 2001. A control study of risperidone in combination with clozapine in treating refractory schizophrenia. *J Mod Clin Med Bioeng*, 7, 100-102.
- Preskorn, S. H. 2010. CNS drug development: part I: the early period of CNS drugs. *Journal of Psychiatric Practice®*, 16, 334-339.
- Purwandityo, A. G., Febrianti, Y., Sari, C. P., Ningrum, V. D. A. & Sugiyarto, O. P. 2018. The Influence of Antipsychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component. *Indonesian Journal of Clinical Pharmacy*, 7, 19-29.
- Ravanic, D. B., Dejanovic, S. M. D., Janjic, V., Jovic, S. D., Milovanovic, D. R., Jakovljevic, V., Pantovic, V., Ravanic, B., Pantovic, M. & Pantovic, M. M. 2009. Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period. *Arquivos de neuro-psiquiatria*, 67, 195-202.
- Rosen, K. & Garety, P. 2005. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. *Schizophrenia bulletin*, 31, 735-750.
- Salam, R., Budiman R., Bastaman TK., Yuniar S., Damping C., Kusumawardhani A., Purnamawati YD. & S., W. 1994. *Pedoman Definisi PANSS (Positive and Negative Symptoms Scale)*, Jakarta, FK Universitas Indonesia Bagian Psikiatri.



- Saperstein, A. M. & Kurtz, M. M. 2013. Current trends in the empirical study of cognitive remediation for schizophrenia. *The Canadian Journal of Psychiatry*, 58, 311-318.
- Savioli, W. K. 2009. The Relationship Between Perceived Stress and Smoking: Focusing on Schizophrenia and Comparative Sub-Groups Diagnosed with Mental Illness.
- Seeman, M. V. 2004a. Gender differences in the prescribing of antipsychotic drugs. *American Journal of Psychiatry*, 161, 1324-1333.
- Seeman, P. 2004b. Atypical antipsychotics: mechanism of action. *Focus*, 47, 27-58.
- Setiati, E., Sumarni, D. & Suryawati, S. 2017. Dukungan sosial dan ketaatan pengobatan dengan kekambuhan pasien skizofrenia di Purworejo. *Berita Kedokteran Masyarakat*, 33, 305-310.
- Shen, W. W. 1999. A history of antipsychotic drug development. *Comprehensive psychiatry*, 40, 407-414.
- Stroup, T. S., Gerhard, T., Crystal, S., Huang, C. & Olfson, M. 2016. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. *Am J Psychiatry*, 173, 166-73.
- Sugandi, C., Rozalina. & Kahtan, M. I. 2017. Perbedaan Skor Positive and Negative Syndrome Scale (PANSS) Awal dan Akhir Terhadap Status Kekambuhan Gangguan Pada Pasien Skizofrenia Rawat Inap di Rumah Sakit Jiwa Daerah Sungai Bangkok Kota Pontianak. *Jurnal Mahasiswa PSPD FK Universitas Tanjungpura*, volume 4.
- Tandon, R. 2019. Pharmacological Treatment of Schizophrenia 2017-2018 Update Summary. *medicaidmentalhealth.org*.
- Tandon, R., Keshavan, M. S. & Nasrallah, H. A. 2008. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. *Schizophr Res*, 102, 1-18.
- Tiihonen, J., Taipale, H., Mehtala, J., Vattulainen, P., Correll, C. U. & Tanskanen, A. 2019. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. *JAMA Psychiatry*, 76, 499-507.
- Üçok, A., Karadayı, G., Emiroğlu, B. & Sartorius, N. 2013. Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia. *Psychiatry research*, 209, 333-339.

- Utami, R. N. 2016. *Evaluasi Penggunaan Antipsikotik Pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Prof. Dr. Soerojo Magelang*. Universitas Gadjah Mada.
- Wardani, I. Y. & Dewi, F. A. 2018. Kualitas Hidup Pasien Skizofrenia Dipersepsikan Melalui Stigma Diri. *Jurnal Keperawatan Indonesia*, 21, 17-26.
- Weinberger, D. L. P. 2011. Schizophrenia as a neurodevelopmental disorder. In: WEINBERGER DR & HARRISON P (eds.) *Schizophrenia, 3rd ed*. Oxford, UK: Wiley-Blackwell.
- Wells, B. G., DiPiro, J. T., Matzke, G. R. & Posey, L. M. 2012. *Pharmacotherapy handbook 8th edition*, McGraw-Hill Medical Pub. Division.
- Xin, X.-f., Du, B.-c. & Zeng, Z.-x. 2001. A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia. *Herald Med*, 20, 501-502.
- Ziedonis, D. M., Kosten, T. R., Glazer, W. M. & Frances, R. J. 1994. Nicotine dependence and schizophrenia. *Psychiatric Services*, 45, 204-206.